ME01600B - MIKRORNK (MIRNK) MIR-21 ZA DIJAGNOZU l TERAPEUTSKE SVRHE - Google Patents

MIKRORNK (MIRNK) MIR-21 ZA DIJAGNOZU l TERAPEUTSKE SVRHE

Info

Publication number
ME01600B
ME01600B MEP-2013-93A MEP9313A ME01600B ME 01600 B ME01600 B ME 01600B ME P9313 A MEP9313 A ME P9313A ME 01600 B ME01600 B ME 01600B
Authority
ME
Montenegro
Prior art keywords
fibrosis
mir
present
treatment
microrna
Prior art date
Application number
MEP-2013-93A
Other languages
English (en)
Inventor
Thomas Thum
Johann Bauersachs
Stefan Engelhardt
Carina Gross
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of ME01600B publication Critical patent/ME01600B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)

Abstract

Ovaj  pronalazak   se odnosi na   promotor ski  region  iz   mikroRNK ,  na  u potrebu  mikroRNK ,  a posebno  miR-21,  i na  slične   element e za  dijagnoz u i za proizvodnju leka za  tretm a n  i / ili   prevencij u  fibroz e i / ili   bolesti koje su povezane sa  fibroz om .  Dodatno ,  ovaj  pronalazak   se odnosi na  antisense - oligo nukleotid e protiv meta  miR-21.  Ćelija koja ne sadrži  miR-21,  promotor ski  region  i mete  miR-21  i  nok aut - organi zam  s u takođe obuhvaćeni sa ovim pronalaskom .  Konačno ,  ovaj  pronalazak   je usmeren na  postupak   za  di j agno zu   fibroz e i / ili   bolesti koje su povezane sa  fibroz om i na  postupak   za pretragu farmaceutski  a k tiv nog   jedinjenj a za  tretm a n   fibroz e i / ili bolesti koje su povezane sa  fibroz om .  Ovaj  pronalazak   dodatno  se odnosi na   kompozicije   za upotrebu u  tretm a n u ,  ublažavanju i / ili   prevencij i   fibroz e .  U   nekim   izvedb ama ,  pomenute  kompozicije  modul iraju delovanje  mi RNK   tokom   tretm a n a ,  ublažavanj a  i / ili   prevencij e   fibroz e .  U   nekim   izvedb ama ,  pomenute k ompozicije  inhibi raju delovanje  miR-21  tokom   tretm a n a ,  ublažavanj a  i / ili   prevencij e   fibroz e .
MEP-2013-93A 2008-02-27 2009-02-26 MIKRORNK (MIRNK) MIR-21 ZA DIJAGNOZU l TERAPEUTSKE SVRHE ME01600B (me)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3183508P 2008-02-27 2008-02-27
EP20080003570 EP2096171A1 (en) 2008-02-27 2008-02-27 MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US3334008P 2008-03-03 2008-03-03
PCT/EP2009/051986 WO2009106477A1 (en) 2008-02-27 2009-02-19 Microrna (mirna) and down-stream targets for diagnostic and therapeutic purposes
PCT/EP2009/001590 WO2009106367A1 (en) 2008-02-27 2009-02-26 Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
EP09714079.2A EP2260101B1 (en) 2008-02-27 2009-02-26 Microrna (mirna) mir-21 for diagnostic and therapeutic purposes

Publications (1)

Publication Number Publication Date
ME01600B true ME01600B (me) 2014-09-20

Family

ID=39639202

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-93A ME01600B (me) 2008-02-27 2009-02-26 MIKRORNK (MIRNK) MIR-21 ZA DIJAGNOZU l TERAPEUTSKE SVRHE

Country Status (23)

Country Link
US (10) US8236777B2 (me)
EP (3) EP2096171A1 (me)
JP (2) JP6033527B2 (me)
KR (1) KR101697482B1 (me)
CN (1) CN102027113B (me)
AU (1) AU2009218704C1 (me)
BR (1) BRPI0907565B1 (me)
CA (2) CA3123067A1 (me)
CY (1) CY1114426T1 (me)
DK (1) DK2260101T3 (me)
EA (1) EA020335B1 (me)
ES (1) ES2436885T3 (me)
HR (1) HRP20130766T1 (me)
IL (1) IL207704A (me)
ME (1) ME01600B (me)
MX (2) MX336299B (me)
MY (1) MY159454A (me)
NZ (1) NZ588185A (me)
PL (1) PL2260101T3 (me)
PT (1) PT2260101E (me)
SI (1) SI2260101T1 (me)
UA (1) UA100727C2 (me)
WO (2) WO2009106477A1 (me)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US20110190372A1 (en) * 2009-08-07 2011-08-04 New York University Compositions and methods for treating inflammatory disorders
CN102038959B (zh) * 2009-10-26 2012-12-19 中国科学院上海生命科学研究院 let-7/miR-98家族在制备治疗FAS基因相关疾病的药物中的应用
WO2011126842A2 (en) * 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
WO2011154553A2 (en) 2010-06-11 2011-12-15 Cellartis Ab Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
AR084319A1 (es) * 2010-12-15 2013-05-08 Miragen Therapeutics INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
WO2012148952A1 (en) * 2011-04-25 2012-11-01 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
EP4008786A3 (en) * 2011-09-06 2022-08-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. The mirna-212/132 family as a therapeutic target
CA2850223A1 (en) 2011-10-06 2013-04-11 Eva Van Rooij Control of whole body energy homeostasis by microrna regulation
EP2592145A1 (en) * 2011-11-11 2013-05-15 Medizinische Hochschule Hannover Medicament for the treatment of cardiac disease
BR112014012288A2 (pt) * 2011-11-22 2017-05-23 Intermune Inc métodos para diagnosticar e tratar fibrose pulmonar idiopática
CA2859430A1 (en) * 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
EP2836219A1 (en) * 2012-04-10 2015-02-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for the treatment of nonalcoholic steatohepatitis
EP2841579B1 (en) * 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CA2782942C (en) 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US11007221B2 (en) 2013-07-12 2021-05-18 Canadian Blood Services Acellular pro-inflammatory compositions, process for making same and methods of using same
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
WO2015086828A1 (en) * 2013-12-12 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
CA2954440A1 (en) 2014-07-10 2016-01-14 Canadian Blood Services Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system
WO2016040373A1 (en) * 2014-09-08 2016-03-17 MiRagen Therapeutics, Inc. Mir-29 mimics and uses thereof
CN107636003A (zh) 2015-01-20 2018-01-26 米拉根医疗股份有限公司 miR‑92抑制剂及其用途
CN106924757B (zh) * 2015-12-31 2020-07-24 中国科学院遗传与发育生物学研究所 miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用
CN107034216A (zh) * 2016-02-04 2017-08-11 中国科学技术大学 miRancer分子的设计与应用
KR101835018B1 (ko) 2016-03-03 2018-03-06 고려대학교 산학협력단 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11667916B2 (en) 2017-09-08 2023-06-06 Korea University Research And Business Foundation Composition for preventing or treating liver fibrosis, containing exosome or exosome-derived ribonucleic acid
CN107858419A (zh) * 2017-11-10 2018-03-30 青岛大学 miRNA的应用、应用其的产品及检测方法
AU2019272190B2 (en) 2018-05-25 2022-12-01 Bioneer Corporation Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
CN109498642A (zh) * 2018-12-21 2019-03-22 复旦大学附属中山医院 一种柯萨奇b3病毒感染导致的心脏微血管病变的靶向治疗药物
US12618067B2 (en) 2020-04-09 2026-05-05 Technische Universität München Targeted delivery of an inhibitor of miR-21 to macrophages for the treatment of pulmonary fibrosis
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
WO2022026851A1 (en) * 2020-07-31 2022-02-03 The Scripps Research Institute Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna
WO2022184888A2 (en) * 2021-03-05 2022-09-09 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for use in the treatment of corneal dystrophies
KR102549208B1 (ko) * 2021-04-08 2023-06-30 연세대학교 산학협력단 심혈관 질환과 관련된 LncRNA 및 이의 용도
CN118667869B (zh) * 2024-07-10 2025-06-27 中国水稻研究所 水稻氮素利用基因nu4在调控水稻生长中的应用
EP4741501A1 (en) 2024-11-11 2026-05-13 RNATICS GmbH Dosing of oligonucleotide drugs targeting mir-21 for inhalation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768139A (zh) * 2003-02-10 2006-05-03 独立行政法人产业技术总合研究所 通过dna干扰调控基因的表达
US8653252B2 (en) 2003-03-21 2014-02-18 Santaris Pharma A/S Short interfering RNA (siRNA) analogues
KR20150132601A (ko) * 2003-11-17 2015-11-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
WO2005111211A2 (en) 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
US20060142193A1 (en) * 2004-11-09 2006-06-29 Baylor College Of Medicine Selective inhibition of rock1 in cardiac therapy
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
JP2010505427A (ja) * 2006-10-09 2010-02-25 ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes

Also Published As

Publication number Publication date
KR20100126430A (ko) 2010-12-01
AU2009218704B2 (en) 2014-09-18
US20230028937A1 (en) 2023-01-26
US20160177302A1 (en) 2016-06-23
AU2009218704A1 (en) 2009-09-03
US20200069720A1 (en) 2020-03-05
US9663788B2 (en) 2017-05-30
EP2260101B1 (en) 2013-05-29
JP6033527B2 (ja) 2016-11-30
CN102027113A (zh) 2011-04-20
NZ588185A (en) 2012-11-30
SI2260101T1 (sl) 2013-10-30
MX2010009346A (es) 2010-12-20
BRPI0907565B1 (pt) 2021-11-30
UA100727C2 (ru) 2013-01-25
EP2096171A1 (en) 2009-09-02
EP2628800A1 (en) 2013-08-21
MX336299B (es) 2016-01-14
KR101697482B1 (ko) 2017-01-18
US20180360866A1 (en) 2018-12-20
US20170304347A1 (en) 2017-10-26
CA2716643C (en) 2021-08-03
US20140121264A1 (en) 2014-05-01
US20240189339A1 (en) 2024-06-13
WO2009106477A1 (en) 2009-09-03
JP2015107971A (ja) 2015-06-11
US20210113603A1 (en) 2021-04-22
US8236777B2 (en) 2012-08-07
CN102027113B (zh) 2017-08-18
US20130018084A1 (en) 2013-01-17
MY159454A (en) 2017-01-13
IL207704A0 (en) 2010-12-30
HRP20130766T1 (hr) 2013-10-25
CA3123067A1 (en) 2009-09-03
US8592389B2 (en) 2013-11-26
WO2009106367A1 (en) 2009-09-03
EA201070992A1 (ru) 2011-04-29
JP2011516410A (ja) 2011-05-26
IL207704A (en) 2016-11-30
AU2009218704C1 (en) 2015-01-29
HK1150857A1 (en) 2012-01-13
US10434117B2 (en) 2019-10-08
DK2260101T3 (da) 2013-08-19
PL2260101T3 (pl) 2013-10-31
US10028974B2 (en) 2018-07-24
EP2260101A1 (en) 2010-12-15
EA020335B1 (ru) 2014-10-30
US9220722B2 (en) 2015-12-29
CA2716643A1 (en) 2009-09-03
PT2260101E (pt) 2013-09-05
CY1114426T1 (el) 2016-08-31
ES2436885T3 (es) 2014-01-07
BRPI0907565A2 (pt) 2019-05-28
US20110071211A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
MX336299B (es) Objetivos de microacido ribonucleico (miarn) y en direccion 3' para propositos de diagnostico y terapeuticos.
WO2009048932A3 (en) Methods to regulate mirna processing by targeting lin-28
HRP20201740T1 (hr) Postupci liječenja progresivnog oblika multiple skleroze
NZ599997A (en) Seed treatment compositions and methods
SI2999785T1 (en) SERPINA1 IRNA assemblies and procedures for their use
WO2009058907A3 (en) Targeting micrornas for the treatment of liver cancer
WO2009045356A3 (en) Microrna compositions in the treatment of vegf-mediated disorders
HRP20211706T1 (hr) Nukleazom posredovana regulacija ekspresije gena
HK1197276A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
DK2437749T3 (da) Kombineret fremgangsmåde til behandling af kræft eller en præcancerøs tilstand
WO2012109476A3 (en) Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements
WO2009117241A3 (en) Controlled degradation of magnesium stents
WO2013030778A3 (en) Organic compositions to treat hsf1-related diseases
MY160249A (en) Fatty acid fumarate derivatives and their uses
MY184925A (en) Crystalline form of benzylbenzene sglt2 inhibitor
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
EA201391492A1 (ru) Соединения на основе микрорнк и способы модулирования активности mir-21
WO2007131232A8 (en) Compositions and their uses directed to ptpr alpha
BR112013006355A2 (pt) profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais
WO2012142313A3 (en) Micro-rna inhibitors and their uses in disease
WO2011071535A3 (en) Compositions and methods for inhibiting human host cell factors required for influenza virus replication
PH12014500990A1 (en) Methods for treating gout flares
ZA202207211B (en) Peptide docking vehicle for targeted nucleic acid delivery
NO333254B1 (no) Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom.
MX2020013865A (es) Tratamiento genico combinatorio.